Summary & Overview
CPT 60660: Percutaneous Radiofrequency Ablation of Thyroid Nodule(s)
CPT code 60660 covers percutaneous radiofrequency ablation of one or more thyroid nodules on a single lobe or the isthmus, with imaging guidance included. This minimally invasive procedure has grown in clinical relevance as an alternative to surgery for selected patients with symptomatic or cosmetically concerning benign thyroid nodules. Nationally, accurate coding and consistent coverage policies for image-guided thermal ablation affect access, utilization patterns, and payment consistency across payers.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how payers typically approach coverage for image-guided thyroid nodule ablation and highlights benchmarks for service setting, coding practice, and common modifiers used in billing.
Readers will gain a concise understanding of the clinical and procedural scope of CPT code 60660, typical sites of service where the procedure is delivered, and the payer landscape relevant to reimbursement and coverage determinations. The report also summarizes practical billing considerations and common coding adjacencies where data are available. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 60660 describes a percutaneous radiofrequency ablation procedure in which the provider destroys one or more thyroid nodules located on a single lobe or the isthmus. The procedure is performed through the skin and includes imaging guidance as part of the service.
-
Service type: Percutaneous radiofrequency ablation of thyroid nodule(s)
-
Typical site of service: Outpatient procedure setting such as an ambulatory surgery center or hospital outpatient department; may also be performed in specialized radiology or endocrinology procedure suites where percutaneous image-guided interventions are offered.
Clinical & Coding Specifications
Clinical Context
A 52-year-old female presents with a symptomatic benign thyroid nodule in the right lobe causing local compressive symptoms (neck fullness and intermittent dysphagia) and cosmetic concern. Ultrasound confirms a 2.5 cm solid predominant nodule without suspicious sonographic features and fine-needle aspiration returned benign cytology. After multidisciplinary discussion, the interventional endocrinologist schedules ultrasound-guided percutaneous radiofrequency ablation (RFA) of the targeted thyroid nodule under conscious sedation in an outpatient procedural suite.
The clinical workflow: pre-procedure evaluation includes focused history, medication reconciliation (anticoagulation management), informed consent, and targeted ultrasound mapping of nodule size and location. On procedure day the patient undergoes time-out, local anesthesia with possible light sedation, and continuous ultrasound imaging for needle placement and thermal monitoring. The RFA probe is advanced percutaneously into the nodule and energy is delivered to achieve ablation of the targeted tissue; the procedure includes real-time ultrasound guidance and post-ablation ultrasound to document immediate treatment effect and rule out complications. The patient is observed in recovery, given discharge instructions, and scheduled for follow-up ultrasound and clinic visit to document nodule volume reduction and symptom improvement.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component |